The Problem: We Don’t Really Know! The problem with estimating the total cost burden of the autoimmune disease (AIID) epidemic is that we really don’t know! A May 2022 NIH report validates our long-held belief that missing and inconsistent data for autoimmune diseases (AIIDs) are at the root of the
Data Issues in Autoimmune Data for autoimmune diseases are substantially lacking and inconsistent. The US gathers no statistics on autoimmune diseases as a group, nor even national data on marquee diseases. Therefore, total autoimmune incidence & prevalence figures are, at best, estimates. Unlike cancer, there is no national strategic research
Many Convoluted Stages Along AIID Patient Journeys The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Each stage presents challenges that may cause patients to drop out before they get the care they need. Unlike cancer, diabetes, and heart disease, there are no population screening
Consulting – Part of Your Team We help digital health and virtual-first companies tackle the invisible epidemic of chronic immuno-inflammatory disorders (CIIDs), including autoimmune and now long COVID. We provide professional services to fill gaps in our clients’ strategic communications and content development programs. We bring multidisciplinary perspectives to our
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Invisible Epidemic of Autoimmune Disease As we continue to illuminate the hidden costs of the long-ignored epidemic of autoimmune disease (AIID), we must shine a light on the highest autoimmune cost: Specialty pharmaceuticals. Current data largely underestimate total AIID costs, and accurate numbers are few and far between. Through our
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
Bridging the Gap Working with digital health companies to advance care for chronic immunoinflammatory disorders. Providing resources for autoimmune patients, caretakers, entrepreneurs and stakeholders. Consulting Services Patient Resources Who We Are Our Vision: A world where people with chronic immunoinflammatory conditions get the best care possible, drawing on conventional, digital and functional medicine. Our
We have noticed much confusion among our broad digital health/virtual-first care network about the definitions of conventional, lifestyle, functional and alternative medicine. To add to the confusion, each picks and chooses techniques from the others to incorporate into their approach. For more than a decade, our team has focused on
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
